Form 4: TScan Therapeutics Director Receives Stock Option Grant
Statement of Changes in Beneficial Ownership
Director Barbara Klencke was granted 67,000 stock options in TScan Therapeutics, Inc. as part of a standard equity compensation arrangement.
Summary
- Director Barbara Klencke received a grant of 67,000 stock options on May 20, 2026.
- The options have an exercise price of $0.9946 per share.
- The options are set to expire on May 20, 2036.
- Vesting occurs in full on the earlier of May 20, 2027, or the date of the next annual stockholders' meeting, contingent on continued service.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative disclosure regarding director compensation with no material impact on the company's operational outlook.
Positives
- Aligns director interests with long-term shareholder value through equity-based compensation.
Negatives
- Results in potential future dilution of existing shareholders upon exercise of the options.
Risks
- The value of the options is dependent on the future market performance of TScan Therapeutics' common stock.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of an equity grant to a director.
Industry Context
StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise, particularly for companies in the clinical development stage.
Comparison to Industry Standards
- The grant size and vesting schedule are consistent with typical compensation packages for directors in small-cap biotech firms.
- The use of a one-year cliff vesting period is a common governance practice to ensure director retention.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of 67,000 stock options to Director Barbara Klencke. | 05/20/2026 | Standard equity alignment; no change to board structure or governance policies. |
Stakeholder Impact
- Shareholders may experience minor dilution if these options are exercised in the future.
Next Steps
- Vesting of options on May 20, 2027, or the next annual meeting.
Key Dates
| Date | Description |
|---|---|
| 05/20/2026 | Date of the stock option grant transaction. |
| 05/20/2027 | Vesting date for the granted stock options. |
| 05/20/2036 | Expiration date for the granted stock options. |
Keywords
TScan Therapeutics, TCRX, Form 4, Insider Trading, Stock Options, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.